Search
Now showing items 1-3 of 3
Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa
(Massachusetts Medical Society., 2014-07-17)
Background
The efficacy and toxic effects of nucleoside reverse-transcriptase inhibitors (NRTIs) are uncertain when these agents are used with a protease inhibitor in second-line therapy for human immunodeficiency virus ...
Assessment of a Pilot Antiretroviral Drug Therapy Programme in Uganda: Patients' Response, Survival, and Drug Resistance
(Elsevier, 2002-07-06)
Background
Little is known about how to implement antiretroviral treatment programmes in resource-limited countries. We assessed the UNAIDS/Uganda Ministry of Health HIV Drug Access Initiative—one of the first pilot ...
Lopinavir Plus Nucleoside Reverse-transcriptase Inhibitors, Lopinavir Plus Raltegravir, or Lopinavir Monotherapy for Second-line Treatment of HIV (EARNEST): 144-week Follow-up Results From a Randomised Controlled Trial
(Elsevier, 2018-01)
Background Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir ...